

References

I-193

1. Vyxeos (daunorubicin and cytarabine) liposome. [prescribing information] Jazz Pharmaceuticals, Inc., Palo Alto, CA. 08/2017.
2. National Comprehensive Cancer Network (NCCN). *NCCN Drugs & Biologics Compendium*. Daunorubicin and Cytarabine Liposome (Vyxeos). 1.2018.
3. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018. Vyxeos.
4. Stein E & Tallman M. Emerging Therapeutic Drugs for AML. *Blood*. 2016;157:71-78.
5. Chen E, Fathi A & Brunner A. Reformulating Acute Myeloid Leukemia: Liposomal Cytarabine and Daunorubicin (CPX-351) as an Emerging Therapy for Secondary AML. *Onco Targets and Therapy*. 2018;11:3425-3434.